PDE5 inhibitors

In this second of two fall reports on treatment development for Duchenne muscular dystrophy, news about ARM210, CAP-1002, PDE5 inhibitors, drisapersen and CAT-1004 is presented

posted on December 4, 2014 - 3:13pm
  Update (Feb. 6, 2015): This article has been amended to show that Catabasis' compound CAT-1004 is expected to move into clinical testing in boys with DMD during the first half of 2015. =======================================================================================================================

A pilot trial has found that one dose of tadalafil or sildenafil increased blood flow to Duchenne MD-affected muscles; a large tadalafil trial recently opened

posted on May 8, 2014 - 10:37am
A study conducted in 10 boys with Duchenne muscular dystrophy (DMD) has found that blood flow to exercising muscles is deficient and that treatment with either tadalafil (Cialis) or sildenafil (Viagra) normalizes this blood flow, at least in the short term (after one dose of either drug). Tadalafil and sildenafil, both PDE5 inhibitors, are approved by the U.S. Food and Drug Administration (FDA)...

An MDA-supported study shows that tadalafil, used to treat erectile dysfunction and pulmonary hypertension, enhances blood flow to exercising forearm muscles in Becker MD

posted on November 28, 2012 - 12:00pm
Update (Sept. 5, 2013): This news item was updated to reflect that none of the trials listed is currently open to new participants.